Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
GRID1 antisense RNA 2 (GRID1-AS2) is a long non-coding RNA transcribed antisense to the GRID1 locus, likely functioning as a regulator of the GRID1 gene or neighboring genes. Like other antisense lncRNAs, it may exert its function via RNA-DNA, RNA-RNA, or RNA-protein interactions, often influencing chromatin structure or mRNA stability. There is no current evidence that it is a therapeutic target or directly associated with disease, although antisense lncRNAs as a class have roles in gene regulation and can impact cellular processes important in health and disease[1][3][5].\n\nIn summary, GRID1-AS2 is a gene regulatory lncRNA, not a standard therapeutic target, and currently lacks characterized disease associations or drug interactions.
Not established for any drug (as no direct drug interactions). Antisense lncRNAs in general can modulate gene expression by base-pairing with sense mRNA, affecting stability, translation, and/or splicing
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on GRID1 antisense RNA 2 (GRID1-AS2).